Christopher Coss, PhD

College

College of Pharmacy

Academic Title

Res Asst Professor

Research Program

Molecular Carcinogenesis and Chemoprevention

Christopher Coss, PhD, is a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, where he brings a therapeutics perspective.

His research focuses on cachexia therapeutics, endocrine-disease mechanisms and development of novel therapies for endocrine cancers. He also is exploring chemoprevention of prostate and hepatocellular carcinomas using novel hormonal approaches.

Among his recent research efforts is the first report of the pharmacokinetics of AR-42, a new orally bioavailable, potent, hydroxamate-tethered phenylbutyrate class I/IIB histone deacetylase inhibitor that is now in early-phase clinical trials.

Dr. Coss has co-authored several articles in well-respected publications, such as Investigational New Drugs, The American Association of Pharmaceutical Scientists Journal and Biochemistry.

Education and Background

614-688-1309

coss.16@osu.edu

Publications

Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer.

Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R

Cancer Res in press 10/04/2017
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC

Leuk Lymphoma 58 2310-2318 10/01/2017
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA

PLoS One 12 e0181885 01/01/2017
Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Coss CC, Jones A, Dalton JT

Invest New Drugs 34 458-67 08/01/2016
Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides.

Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss CC, Phelps M, Rossman JS, Pei D, Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss C, Phelps MA, Rossman JS, Pei D

Biochemistry 55 2601-12 05/10/2016
Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides.

Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss CC, Phelps M, Rossman JS, Pei D, Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss C, Phelps MA, Rossman JS, Pei D

Biochemistry 55 2601-12 05/10/2016
Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

Phelps M, Coss C, Wang H, Cook M, Reproducibility Project: Cancer Biology, Reproducibility Project Cancer Biology

Elife 5 03/01/2016
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.

Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC

PLoS One 11 e0159607 01/01/2016
Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.

Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan KK

AAPS J 18 737-45 01/01/2016

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

Christopher Coss, PhD

College

Academic Title

Research Program

Education and Background

Publications

Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides.

Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides.

Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.

Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

Christopher Coss, PhD

College

Academic Title

Research Program

Education and Background

Publications

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication